PAVmed Signs Letter of Intent to License Groundbreaking Endoscopic Esophageal Imaging Technology

Newly-formed PAVmed subsidiary to license endoscopic imaging technology designed to identify and facilitate ablative treatment of esophageal dysplasiaLucid Diagnostics to collaborate with PAVmed as a strategic and equity partner on the technologyNEW YORK, Aug. 26, 2025 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors,  today announced that it has executed ...